S Shalitin1,2, V Deutsch3,4, R Tauman5,4. 1. The Jesse Z. and Lea Shafer, Institute for Endocrinology and Diabetes, National Center for Childhood Diabetes, Schneider Children's Medical Center of Israel, 14 Kaplan St., 49202, Petach Tikva, Israel. shalitin@netvision.net.il. 2. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. shalitin@netvision.net.il. 3. The Hematology Institute, Tel Aviv Medical Center, Tel Aviv, Israel. 4. Sackler School of Medicine, Tel Aviv University, Tel Aviv, Israel. 5. Pediatric Sleep Laboratory, Dana Children's Hospital, Tel Aviv Medical Center, Tel Aviv, Israel.
Abstract
PURPOSE: Obesity, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA) are associated with chronic low-grade inflammation. Iron metabolism is linked with insulin-resistant states and with OSA in adults. The association of body iron status with T2DM in children remains undefined. We aimed to evaluate plasma interleukin-6 (IL-6), hepcidin, and soluble transferrin receptor (sTfR) levels in obese patients with T2DM or impaired glucose tolerance (IGT) and in those without, and the contribution of OSA to their levels. METHODS: In this cross-sectional study, obese children and adolescents with and without T2DM/IGT underwent overnight polysomnography. Fasting plasma concentrations of IL-6, hepcidin, and sTfR were measured and evaluated according to glycemic status (T2DM/IGT and normal glucose tolerance) and the presence of OSA. RESULTS: Ten patients with T2DM (age 15.9 ± 3.6 years), 8 with IGT (age 13.1 ± 2.5 years) and 20 subjects with normal glucose tolerance matched for body mass index standard deviation score (age 12.6 ± 3.3 years) were studied. Sleep measures or IL-6, hepcidin, and sTfR levels were not significantly different between the group with T2DM/IGT vs. the control group. No significant differences were found in hepcidin or sTfR levels between patients with OSA and those without. However, patients with OSA showed higher plasma IL-6 values compared with those without (4.56 ± 2.92 vs. 2.83 ± 1.54 pg/ml, P = 0.025), and the highest values were evident in patients affected by both T2DM/IGT and OSA. CONCLUSIONS: Higher IL-6 levels were associated with both glycemic status and OSA. No differences in body iron regulator levels were found in obese patients with T2DM/IGT compared to those without or in those with OSA compared to those without. Further longitudinal studies in larger population samples are warranted.
PURPOSE: Obesity, type 2 diabetes mellitus (T2DM), and obstructive sleep apnea (OSA) are associated with chronic low-grade inflammation. Iron metabolism is linked with insulin-resistant states and with OSA in adults. The association of body iron status with T2DM in children remains undefined. We aimed to evaluate plasma interleukin-6 (IL-6), hepcidin, and soluble transferrin receptor (sTfR) levels in obesepatients with T2DM or impaired glucose tolerance (IGT) and in those without, and the contribution of OSA to their levels. METHODS: In this cross-sectional study, obesechildren and adolescents with and without T2DM/IGT underwent overnight polysomnography. Fasting plasma concentrations of IL-6, hepcidin, and sTfR were measured and evaluated according to glycemic status (T2DM/IGT and normal glucose tolerance) and the presence of OSA. RESULTS: Ten patients with T2DM (age 15.9 ± 3.6 years), 8 with IGT (age 13.1 ± 2.5 years) and 20 subjects with normal glucose tolerance matched for body mass index standard deviation score (age 12.6 ± 3.3 years) were studied. Sleep measures or IL-6, hepcidin, and sTfR levels were not significantly different between the group with T2DM/IGT vs. the control group. No significant differences were found in hepcidin or sTfR levels between patients with OSA and those without. However, patients with OSA showed higher plasma IL-6 values compared with those without (4.56 ± 2.92 vs. 2.83 ± 1.54 pg/ml, P = 0.025), and the highest values were evident in patients affected by both T2DM/IGT and OSA. CONCLUSIONS: Higher IL-6 levels were associated with both glycemic status and OSA. No differences in body iron regulator levels were found in obesepatients with T2DM/IGT compared to those without or in those with OSA compared to those without. Further longitudinal studies in larger population samples are warranted.
Authors: Marina Cardellini; Francesco Andreozzi; Emanuela Laratta; Maria Adelaide Marini; Renato Lauro; Marta Letizia Hribal; Francesco Perticone; Giorgio Sesti Journal: Diabetes Metab Res Rev Date: 2007-02 Impact factor: 4.876
Authors: Kanakadurga Singer; Donna S Eng; Carey N Lumeng; Achamyeleh Gebremariam; Joyce M Lee Journal: Obesity (Silver Spring) Date: 2014-02-18 Impact factor: 5.002
Authors: Anthony J G Hanley; Andreas Festa; Ralph B D'Agostino; Lynne E Wagenknecht; Peter J Savage; Russell P Tracy; Mohammed F Saad; Steven M Haffner Journal: Diabetes Date: 2004-07 Impact factor: 9.461
Authors: S N Rajpathak; J Wylie-Rosett; M J Gunter; A Negassa; G C Kabat; T E Rohan; J Crandall Journal: Diabetes Obes Metab Date: 2009-01-21 Impact factor: 6.577
Authors: J Montonen; H Boeing; A Steffen; R Lehmann; A Fritsche; H-G Joost; M B Schulze; T Pischon Journal: Diabetologia Date: 2012-07-01 Impact factor: 10.122
Authors: Fransina Ndevahoma; Munyaradzi Mukesi; Phiwayinkosi V Dludla; Bongani B Nkambule; Elina P Nepolo; Tawanda M Nyambuya Journal: Heliyon Date: 2021-03-11